These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27655700)

  • 1. Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo.
    Song J; Zhao Z; Fan X; Chen M; Cheng X; Zhang D; Wu F; Ying X; Ji J
    Oncotarget; 2016 Oct; 7(43):70504-70515. PubMed ID: 27655700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB.
    Ma Y; Wang J; Liu L; Zhu H; Chen X; Pan S; Sun X; Jiang H
    Cancer Lett; 2011 Feb; 301(1):75-84. PubMed ID: 21078540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
    Li W; Wang M; Wang L; Ji S; Zhang J; Zhang C
    Cell Biochem Biophys; 2014 Mar; 68(2):427-36. PubMed ID: 23975599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
    Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
    Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression.
    Yang X; Sun D; Tian Y; Ling S; Wang L
    Tumour Biol; 2015 Apr; 36(4):2957-64. PubMed ID: 25492486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo.
    He G; He G; Zhou R; Pi Z; Zhu T; Jiang L; Xie Y
    Biochem Biophys Res Commun; 2016 Jan; 469(4):1075-82. PubMed ID: 26740178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
    Jiang H; Ma Y; Chen X; Pan S; Sun B; Krissansen GW; Sun X
    Cancer Sci; 2010 Apr; 101(4):975-83. PubMed ID: 20219070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
    Liu ZM; Tseng JT; Hong DY; Huang HS
    Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair.
    Luo Q; Li Y; Deng J; Zhang Z
    Chem Biol Interact; 2015 Jan; 226():12-22. PubMed ID: 25499136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells.
    Chen G; Wang K; Yang BY; Tang B; Chen JX; Hua ZC
    Int J Oncol; 2012 Jan; 40(1):139-47. PubMed ID: 21947421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
    Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma.
    Zhu C; Zhou R; Zhou Q; Chang Y; Jiang M
    Life Sci; 2016 Dec; 166():34-40. PubMed ID: 27717846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells.
    Chiu HW; Tseng YC; Hsu YH; Lin YF; Foo NP; Guo HR; Wang YJ
    Cancer Lett; 2015 Jan; 356(2 Pt B):762-72. PubMed ID: 25449439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
    Wang W; Adachi M; Zhang R; Zhou J; Zhu D
    Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of NF-κB in PARP-inhibitor-mediated sensitization and detoxification of arsenic trioxide in hepatocellular carcinoma cells.
    Luo Q; Li Y; Lai Y; Zhang Z
    J Toxicol Sci; 2015 Jun; 40(3):349-63. PubMed ID: 25972196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
    Zheng T; Yin D; Lu Z; Wang J; Li Y; Chen X; Liang Y; Song X; Qi S; Sun B; Xie C; Meng X; Pan S; Liu J; Jiang H; Liu L
    Mol Cancer; 2014 May; 13():133. PubMed ID: 24884809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells.
    Shen P; Jiang T; Lu H; Han H; Luo R
    Cell Biol Int; 2011 Aug; 35(8):803-10. PubMed ID: 21418039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SurvivinT34A increases the therapeutic efficacy of arsenic trioxide in mouse hepatocellular carcinoma models.
    Huang A; Yue D; Liao D; Cheng L; Ma J; Wei Y; Tong A; Cheng P
    Oncol Rep; 2016 Dec; 36(6):3283-3290. PubMed ID: 27748945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergic effect of 3'-azido-3'-deoxythymidine and arsenic trioxide in suppressing hepatoma cells.
    Chen C; Zhang Y; Wang Y; Huang D; Xi Y; Qi Y
    Anticancer Drugs; 2011 Jun; 22(5):435-43. PubMed ID: 21502917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.
    Lee PC; Kakadiya R; Su TL; Lee TC
    Neoplasia; 2010 May; 12(5):376-87. PubMed ID: 20454509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.